Yang Mao‐Draayer

4.1k total citations
85 papers, 2.1k citations indexed

About

Yang Mao‐Draayer is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Immunology. According to data from OpenAlex, Yang Mao‐Draayer has authored 85 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pathology and Forensic Medicine, 24 papers in Molecular Biology and 24 papers in Immunology. Recurrent topics in Yang Mao‐Draayer's work include Multiple Sclerosis Research Studies (44 papers), Immunotherapy and Immune Responses (12 papers) and Peripheral Neuropathies and Disorders (10 papers). Yang Mao‐Draayer is often cited by papers focused on Multiple Sclerosis Research Studies (44 papers), Immunotherapy and Immune Responses (12 papers) and Peripheral Neuropathies and Disorders (10 papers). Yang Mao‐Draayer collaborates with scholars based in United States, Switzerland and France. Yang Mao‐Draayer's co-authors include Elizabeth Mills, Qi Wu, Qin Wang, Steven K. Lundy, Catherine Dowling, Ali Mirza, Guangmei Mao, Jennifer Yang, Chang H. Kim and Jeongho Park and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Yang Mao‐Draayer

79 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yang Mao‐Draayer United States 26 890 811 547 374 349 85 2.1k
Calliope A. Dendrou United Kingdom 15 855 1.0× 872 1.1× 1.3k 2.3× 326 0.9× 216 0.6× 32 2.9k
Yuji Nakatsuji Japan 28 587 0.7× 904 1.1× 470 0.9× 239 0.6× 578 1.7× 94 2.3k
Oliver Neuhaus Germany 22 995 1.1× 333 0.4× 788 1.4× 372 1.0× 484 1.4× 52 2.0k
Catherine Larochelle Canada 25 579 0.7× 498 0.6× 614 1.1× 250 0.7× 218 0.6× 60 1.9k
Ulf Schulze‐Topphoff United States 16 581 0.7× 711 0.9× 814 1.5× 200 0.5× 216 0.6× 22 2.0k
Michel Varrin‐Doyer United States 18 735 0.8× 550 0.7× 690 1.3× 135 0.4× 344 1.0× 19 1.7k
Bernadette Kálmán United States 26 723 0.8× 932 1.1× 483 0.9× 214 0.6× 211 0.6× 83 2.0k
Mariko Kita United States 16 1.1k 1.3× 386 0.5× 480 0.9× 415 1.1× 420 1.2× 31 1.9k
José C. Álvarez‐Cermeño Spain 27 1.4k 1.6× 648 0.8× 569 1.0× 373 1.0× 735 2.1× 87 2.3k
Chuanzhen Lü China 31 561 0.6× 679 0.8× 342 0.6× 166 0.4× 899 2.6× 87 2.5k

Countries citing papers authored by Yang Mao‐Draayer

Since Specialization
Citations

This map shows the geographic impact of Yang Mao‐Draayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang Mao‐Draayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang Mao‐Draayer more than expected).

Fields of papers citing papers by Yang Mao‐Draayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang Mao‐Draayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang Mao‐Draayer. The network helps show where Yang Mao‐Draayer may publish in the future.

Co-authorship network of co-authors of Yang Mao‐Draayer

This figure shows the co-authorship network connecting the top 25 collaborators of Yang Mao‐Draayer. A scholar is included among the top collaborators of Yang Mao‐Draayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang Mao‐Draayer. Yang Mao‐Draayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Feng, et al.. (2025). Ligands of CD6: roles in the pathogenesis and treatment of cancer. Frontiers in Immunology. 15. 1528478–1528478. 1 indexed citations
2.
Abboud, Hesham, Brian Steingo, Diana Vargas, et al.. (2025). Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series. Journal of Neuroimmunology. 403. 578585–578585.
3.
Mills, Elizabeth, Qi Wu, Insha Zahoor, et al.. (2025). New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies. International Journal of Molecular Sciences. 26(8). 3880–3880.
4.
Fox, Robert J., Stanley Cohan, Yang Mao‐Draayer, et al.. (2025). Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study. Multiple Sclerosis Journal. 31(6). 706–718.
5.
Wu, Qi, M. Asif Amin, Pei‐Suen Tsou, et al.. (2024). Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells. Cancer Immunology Immunotherapy. 73(2). 34–34. 6 indexed citations
6.
Siebert, Nadja, Klemens Ruprecht, Gaurav Kumar, et al.. (2024). Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion. Neurology Neuroimmunology & Neuroinflammation. 11(4). e200268–e200268. 1 indexed citations
7.
Mao‐Draayer, Yang, Amit Bar‐Or, John Foley, et al.. (2024). Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances in Therapy. 42(1). 395–412. 2 indexed citations
8.
Giovannoni, Gavin, Cristina Granziera, Yang Mao‐Draayer, et al.. (2024). 151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension. Multiple Sclerosis and Related Disorders. 92. 106112–106112. 1 indexed citations
9.
Vermersch, Patrick, Cristina Granziera, Yang Mao‐Draayer, et al.. (2024). Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine. 390(7). 589–600. 34 indexed citations
10.
Wang, Qin, Ali Mirza, Qi Wu, et al.. (2024). Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis. Scientific Reports. 14(1). 15292–15292. 19 indexed citations
11.
12.
Amin, M. Asif, Phillip L. Campbell, Qi Wu, et al.. (2022). Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight. 7(9). 12 indexed citations
13.
14.
Yang, Jennifer, Qi Wu, Qin Wang, et al.. (2022). Current and Future Biomarkers in Multiple Sclerosis. International Journal of Molecular Sciences. 23(11). 5877–5877. 89 indexed citations
15.
Fadul, Camilo E., Yang Mao‐Draayer, Kathleen A. Ryan, et al.. (2021). Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 8(6). 26 indexed citations
16.
Ruth, Jeffrey H., M. Asif Amin, Phillip L. Campbell, et al.. (2021). CD6 is a target for cancer immunotherapy. JCI Insight. 6(5). 34 indexed citations
17.
Wu, Qi, Bhuwan Khatri, Nadja Borisow, et al.. (2020). Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nature Communications. 11(1). 2856–2856. 64 indexed citations
18.
Park, Jeongho, Qin Wang, Qi Wu, Yang Mao‐Draayer, & Chang H. Kim. (2019). Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation. Scientific Reports. 9(1). 8837–8837. 138 indexed citations
19.
Mills, Elizabeth, et al.. (2018). Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Multiple Sclerosis Journal. 24(14). 1795–1807. 15 indexed citations
20.
Mao‐Draayer, Yang, Qi Wu, Qin Wang, et al.. (2017). Basic Immunological Profile Changes of SPMS Patients Treated with BAF312 (P1.384). Neurology. 88(16_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Calliope A. Dendrou Breakdown of academic impact, for papers by Yuji Nakatsuji Breakdown of academic impact, for papers by Oliver Neuhaus Breakdown of academic impact, for papers by Catherine Larochelle Breakdown of academic impact, for papers by Ulf Schulze‐Topphoff Breakdown of academic impact, for papers by Michel Varrin‐Doyer Breakdown of academic impact, for papers by Bernadette Kálmán Breakdown of academic impact, for papers by Mariko Kita Breakdown of academic impact, for papers by José C. Álvarez‐Cermeño Breakdown of academic impact, for papers by Chuanzhen Lü
Rankless by CCL
2026